Other substances

Isavuconazonium

A triazole antifungal.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
1
 Clinical trials

General information

Isavuconazonium on PubChem

Marketed as

CRESEMBA

 

Structure image - Isavuconazonium

C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O

Supporting references

Link Tested on Impact factor Notes Publication date
Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach
3CLpro Small molecule In silico 		in silico 2.08

Predicted to bind the SARS-CoV-2 3C-like protease.

 Sep/02/2020

AI-suggested references

Link Publication date
Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 alpha-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
Sep/02/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04707703 Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Recruiting Phase 3 Mar/16/2021 Mar/01/2022
  • Alternative id - 200639
  • Interventions - Drug: Isavuconazonium Injection [Cresemba]|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of California Irvine, Orange, California, United States|University of California Davis, Sacramento, California, United States|University of California San Diego, San Diego, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 162
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The incidence of SARS-CoV-2-associated invasive aspergillosis at time of ICU discharge|The incidence of SARS-CoV-2-associated non-Aspergillus invasive fungal infections at time of ICU discharge|Survival|Length of ICU stay|Length of Hospital stay|Mortality|Adverse events
Export (.csv)